electroCore to Participate at the 38th Annual Roth Conference

electroCore, Inc. (Nasdaq: ECOR), a pioneering bioelectronic medicine and wellness company, has announced its participation in the 38th Annual Roth Conference, taking place from March 22-24, 2026, at the Ritz-Carlton in Laguna Niguel, California. Chief Financial Officer Joshua Lev will represent the company by hosting one-on-one meetings during the event. Interested investors are encouraged to arrange meetings through their Roth representatives or by contacting the company directly at investors@electrocore.com.

The Roth Conference is recognized as one of the largest gatherings for small-cap companies in the United States, featuring about 500 private and public companies. It offers a robust platform where company presentations, question-and-answer sessions, and one-on-one meetings enable investors to engage directly with executive management across multiple growth sectors, including healthcare, technology, and industrial growth.

electroCore is committed to enhancing health and quality of life with its innovative non-invasive bioelectronic technologies. The company’s flagship products are designed to alleviate chronic pain syndromes using non-invasive neuromodulation techniques. Notably, its gammaCore device employs vagus nerve stimulation (nVNS) for pain management, while the Quell® Fibromyalgia device addresses the needs of fibromyalgia patients. Additionally, electroCore expands its reach in the wellness space with products like Trvuaga and TAC-STIM, intended for personal use to promote overall wellness and improve human performance.

Investors looking for more detailed information about electroCore and its pioneering technologies can visit the company’s official website at www.electrocore.com. With its participation in the Roth Conference, electroCore aims to further engage with the investment community and highlight its mission of leveraging bioelectronic technologies for enhanced health outcomes.

As electroCore, Inc. (Nasdaq: ECOR) prepares to attend the 38th Annual Roth Conference from March 22-24, 2026, this presents a crucial moment for potential investors looking for insights into the company’s future and market positioning. The Roth Conference is known for showcasing small-cap companies, directly connecting investors with management through one-on-one meetings. This unique format allows attendees to gain valuable insights into electroCore's strategic initiatives and market trends in the bioelectronic medicine sector.

ElectroCore’s focus on non-invasive technologies, particularly its leading products—gammaCore and Quell—positions the company favorably in an expanding market driven by increasing demand for innovative pain management solutions. With a growing awareness of bioelectronic therapies, electroCore is well-poised to take advantage of shifting patient preferences away from pharmacological treatments.

As the Chief Financial Officer, Joshua Lev’s participation suggests a commitment to transparency and investor engagement. Stakeholders should pay close attention to the discussions surrounding reimbursement strategies, product performance, and clinical outcomes that will likely be highlighted during the meetings. These factors can significantly influence investor confidence and the stock’s short- to medium-term performance.

Investors should also consider the competitive landscape; while electroCore stands out, it faces challenges from traditional and new entrants in the bioelectronic arena. Therefore, understanding how the company differentiates its technology through clinical validation and market penetration will be vital.

In conclusion, the upcoming Roth Conference is not just an opportunity for networking; it represents a strategic pivot point for electroCore to reaffirm its market presence. Investors should closely monitor insights from this event, evaluating whether electroCore remains a viable addition to their portfolios based on the management’s outlook and industry trends discussed during the conference.